Inhibition of Tumor Necrosis Factor α and Ankylosing Spondylitis
Open Access
- 23 January 2003
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 348 (4) , 359-361
- https://doi.org/10.1056/nejm200301233480417
Abstract
In a recent multicenter trial, Gorman et al. (May 2 issue)1 found that 80 percent of patients with active ankylosing spondylitis had a favorable response to etanercept. Equivalent results are obtained with infliximab.2 Data on uveitis are still lacking. We report a case of severe uveitis in a 45-year-old man that improved with infliximab.Keywords
This publication has 10 references indexed in Scilit:
- Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor αNew England Journal of Medicine, 2002
- Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trialThe Lancet, 2002
- Assessment of fatigue in patients with ankylosing spondylitis: A psychometric analysisArthritis Care & Research, 2002
- Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximabAmerican Journal of Gastroenterology, 2002
- Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: A clinical and magnetic resonance imaging studyArthritis & Rheumatism, 2001
- Effect of infliximab on sight-threatening panuveitis in Behcet's diseaseThe Lancet, 2001
- Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic diseaseArthritis & Rheumatism, 2001
- Etanercept therapy in children with treatment-resistant uveitisArthritis & Rheumatism, 2001
- Classification of inflammatory arthritis by enthesitisThe Lancet, 1998
- Transgenic Mice Expressing a TruncatedPeromyscus leucopusTNF-α Gene Manifest an Arthritis Resembling Ankylosing SpondylitisJournal of Interferon & Cytokine Research, 1998